Compare GKOS & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | RGEN |
|---|---|---|
| Founded | 1998 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.6B |
| IPO Year | 2015 | 1995 |
| Metric | GKOS | RGEN |
|---|---|---|
| Price | $102.43 | $124.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 12 |
| Target Price | $126.92 | ★ $167.67 |
| AVG Volume (30 Days) | 1.0M | ★ 1.3M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 286.96 |
| EPS | N/A | ★ 0.15 |
| Revenue | ★ $507,442,000.00 | $141,236,000.00 |
| Revenue This Year | $23.32 | $14.30 |
| Revenue Next Year | $27.43 | $14.52 |
| P/E Ratio | ★ N/A | $824.80 |
| Revenue Growth | 32.33 | ★ 35.10 |
| 52 Week Low | $73.16 | $100.99 |
| 52 Week High | $148.11 | $175.77 |
| Indicator | GKOS | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 28.38 | 59.18 |
| Support Level | $92.38 | $121.25 |
| Resistance Level | $102.80 | $129.77 |
| Average True Range (ATR) | 7.36 | 6.49 |
| MACD | -4.94 | 1.57 |
| Stochastic Oscillator | 1.08 | 88.42 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.